Becton, Dickinson and Company (NYSE:BDX) EVP Michael Feld Sells 75 Shares

Becton, Dickinson and Company (NYSE:BDX) EVP Michael Feld sold 75 shares of the stock in a transaction that occurred on Monday, January 26th. The shares were sold at an average price of $202.73, for a total transaction of $15,204.75. Following the completion of the sale, the executive vice president owned 16,431 shares in the company, valued at $3,331,056.63. This represents a 0.45% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Michael Feld also recently made the following trade(s):

• On Friday, December 26th, Michael Feld sold 74 shares of Becton, Dickinson and Company stock. The shares were sold at an average price of $196.08, for a total value of $14,509.92.
• On Monday, December 1st, Michael Feld sold 75 shares of Becton, Dickinson and Company stock. The stock was sold at an average price of $193.36, for a total value of $14,502.00.

Becton, Dickinson and Company Price Performance

NYSE:BDX opened at $201.81 on Thursday. The firm has a market cap of $57.50 billion, a price-to-earnings ratio of 34.62, a price-to-earnings-growth ratio of 2.25 and a beta of 0.23. The company has a current ratio of 1.11, a quick ratio of 0.64 and a debt-to-equity ratio of 0.69. The company’s 50-day moving average is $198.08 and its two-hundred day moving average is $190.98. Becton, Dickinson and Company has a 12-month low of $162.29 and a 12-month high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $3.96 EPS for the quarter, topping analysts’ consensus estimates of $3.92 by $0.04. The business had revenue of $5.89 billion during the quarter, compared to the consensus estimate of $5.91 billion. Becton, Dickinson and Company had a net margin of 7.68% and a return on equity of 16.42%. The company’s quarterly revenue was up 8.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.81 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 14.750-15.050 EPS. Research analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company announced that its Board of Directors has initiated a share repurchase program on Tuesday, January 27th that allows the company to repurchase $10.00 million in outstanding shares. This repurchase authorization allows the medical instruments supplier to purchase up to 0% of its shares through open market purchases. Shares repurchase programs are often an indication that the company’s management believes its shares are undervalued.

Becton, Dickinson and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 31st. Stockholders of record on Tuesday, March 10th will be given a $1.05 dividend. The ex-dividend date of this dividend is Tuesday, March 10th. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.1%. Becton, Dickinson and Company’s payout ratio is currently 72.04%.

Key Stories Impacting Becton, Dickinson and Company

Here are the key news stories impacting Becton, Dickinson and Company this week:

• Positive Sentiment: Board set the record date (Feb 5) and distribution/closing date (Feb 9) for the spin-off of BD’s Biosciences & Diagnostic Solutions business — a structural move that could unlock value for shareholders. BD Announces Record Date for the Spin-Off
• Positive Sentiment: Waters Corporation shareholders approved the combination with BD’s Biosciences & Diagnostic Solutions unit, clearing a key step toward the planned transaction that underpins the spin-off strategy. Waters Shareholders Approve Combination
• Positive Sentiment: Board declared a $1.05 quarterly dividend (payable Mar 31; record/ex-div Mar 10), supporting income-focused investors and signaling cash-return discipline. BD Board Declares Dividend, Authorizes Repurchases
• Positive Sentiment: Company authorized an additional $10 million in share repurchases and has completed ~$250 million of repurchases year-to-date, which can support EPS and signal management confidence (note: $10M is small vs. market cap). Board Authorizes Additional Repurchases
• Positive Sentiment: Launched BD Research Cloud 7.0 with AI-powered features for flow cytometry — product innovation that can drive competitive positioning in diagnostics and recurring software/service revenue over time. BDX Introduces BD Research Cloud 7.0
• Neutral Sentiment: BD will release quarterly earnings and host a management webcast — an upcoming catalyst that could cause short-term volatility depending on results vs. guidance. BD to Release Quarterly Earnings
• Neutral Sentiment: Analyst and media pieces highlight BDX as a long-term value name versus peers; useful for investor sentiment but not an immediate price mover. Why Becton Dickinson is a Top Value Stock
• Negative Sentiment: Insider activity: EVP Michael Feld sold 75 shares (~$15.2k) on Jan 26 — a very small reduction in holdings (0.45% of his stake) that is unlikely to materially affect investor view but may be cited by short-term traders. SEC Form 4 – Michael Feld Sale

Hedge Funds Weigh In On Becton, Dickinson and Company

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Brighton Jones LLC lifted its position in shares of Becton, Dickinson and Company by 98.2% during the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after purchasing an additional 877 shares in the last quarter. Empowered Funds LLC increased its stake in Becton, Dickinson and Company by 20.4% during the 1st quarter. Empowered Funds LLC now owns 7,977 shares of the medical instruments supplier’s stock worth $1,827,000 after buying an additional 1,354 shares during the period. Patton Fund Management Inc. purchased a new position in Becton, Dickinson and Company in the 2nd quarter valued at about $202,000. GC Wealth Management RIA LLC acquired a new stake in shares of Becton, Dickinson and Company during the second quarter valued at about $295,000. Finally, Moss Adams Wealth Advisors LLC purchased a new stake in shares of Becton, Dickinson and Company during the second quarter worth about $231,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. Piper Sandler upped their price target on shares of Becton, Dickinson and Company from $190.00 to $205.00 and gave the stock a “neutral” rating in a research report on Wednesday. Weiss Ratings restated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a report on Wednesday, October 8th. Wall Street Zen cut Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. Morgan Stanley upped their price target on Becton, Dickinson and Company from $197.00 to $210.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 2nd. Finally, Jefferies Financial Group lifted their price target on shares of Becton, Dickinson and Company from $215.00 to $220.00 and gave the company a “buy” rating in a research report on Wednesday, December 10th. Four equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Becton, Dickinson and Company has an average rating of “Hold” and an average target price of $209.00.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.